Mihai Cosmin Stan
Overview
Explore the profile of Mihai Cosmin Stan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
6
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mirestean C, Stan M, Iancu R, Iancu D, Badulescu F
Bratisl Lek Listy
. 2024 Jun;
125(7):457-462.
PMID: 38943508
Increased serum lactate dehydrogenase (LDH) activity is considered as a marker of cellular necrosis and serves as a metabolomic diagnostic marker in several types of cancer including head and neck...
2.
Stan M, Paul D
Oncol Rev
. 2024 Jun;
18:1354549.
PMID: 38835644
This paper presents an overview of the interconnection between various factors related to both cancer and type 2 diabetes mellitus (T2DM). Hyperglycemia, hyperinsulinemia, chronic inflammation, and obesity are involved in...
3.
Mirestean C, Stan M, Iancu R, Iancu D, Badulescu F
Diagnostics (Basel)
. 2023 Nov;
13(22).
PMID: 37998532
Introduction: Neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), and pallets-to-lymphocyte ratio (PLR) are currently validated as cheap and accessible biomarkers in different types of solid tumors, including head and neck cancers...
4.
Stan M, Mirestean C, Stoica D, Popescu F, Badulescu F
Rom J Morphol Embryol
. 2023 Oct;
64(3):411-417.
PMID: 37867358
Background And Aim: Type 2 diabetes (T2D) and cancer, the most important public health problems nowadays, and the mechanisms between the presence of diabetes and the development of malignancies remain...
5.
Mirestean C, Simionescu C, Iancu R, Stan M, Iancu D, Badulescu F
Diagnostics (Basel)
. 2023 Oct;
13(19).
PMID: 37835769
Chondrosarcoma represents approximately 0.1% of all neoplasms of the head and neck and is considered a rare disease with a relatively good prognosis. The 5-year overall survival (OS) rate is...
6.
Stan M, Georgescu D, Mirestean C, Badulescu F
Diagnostics (Basel)
. 2023 Aug;
13(16).
PMID: 37627906
Background And Objectives: A growing number of epidemiological studies have suggested that diabetes mellitus may increase cancer risk and is implicated in numerous other metabolic and inflammatory disorders. The increase...
7.
Mirestean C, Stan M, Schenker M, Volovat C, Volovat S, Iancu D, et al.
Diagnostics (Basel)
. 2023 Aug;
13(16).
PMID: 37627878
Prognosis in recurrent/metastatic head and neck squamous-cell carcinoma (HNSCC) refractory to platinum-based chemotherapy is poor, making therapy optimization a priority. Anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody Nivolumab was...
8.
Mirestean C, Stan M, Badulescu F
Bratisl Lek Listy
. 2023 May;
124(7):549-552.
PMID: 37218484
Diabetes mellitus (DM) and altered glucose metabolism have been associated with carcinogenesis, but also with prognosis and tolerance to treatment in different types of cancer. Head and neck cancers (HNC),...